Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations

Area of Science:

• Oncolytic virotherapy
• Nanomedicine
• Cancer immunotherapy

Background:

• Oncolytic adenoviruses (OAds) are engineered to target and destroy cancer cells, emerging as a key immunotherapy strategy.
• Despite preclinical and clinical successes, OAds face limitations like poor infectivity, immune system evasion, and tumor microenvironment barriers.
• These challenges hinder their widespread therapeutic application in treating various malignancies.

Purpose of the Study:

• To review current OAd constructs and their clinical trial applications.
• To identify the key limitations hindering OAd therapeutic effectiveness.
• To explore the potential of nanotechnology in overcoming OAd-related challenges for improved anti-tumor activity.

Main Methods:

• Literature review of OAd constructs and clinical trial data.
• Analysis of challenges associated with OAd therapy, including infectivity, immune response, and tumor penetration.
• Examination of nanotechnology-based strategies for enhancing OAd delivery and efficacy.

Main Results:

• OAds demonstrate potential but are hampered by issues such as low cancer cell infectivity, liver sequestration, pre-existing neutralizing antibodies, and the immunosuppressive tumor microenvironment (TME).
• Nanotechnology offers promising solutions to enhance OAd infectivity, cellular uptake, immune evasion, and targeted delivery.
• Nanoparticle formulations can mask OAds, prevent liver tropism, and facilitate co-delivery of multiple therapeutic agents.

Conclusions:

• Nanotechnology presents a powerful approach to address the limitations of oncolytic adenoviruses.
• By leveraging nano-sized tools, the therapeutic efficacy of OAds can be significantly improved for enhanced anti-tumor activities.
• Integrating nanotechnology with OAd platforms holds substantial promise for advancing cancer immunotherapy.